Search: onr:"swepub:oai:DiVA.org:uu-430967" >
PD-L1 expression in...
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
-
- Ali, Abir Salwa, 1986- (author)
- Uppsala universitet,Onkologisk endokrinologi
-
Langer, Seppo W. (author)
-
Federspiel, Birgitte (author)
-
show more...
-
Hjortland, Geir Olav (author)
-
Grønbæk, Henning (author)
-
Ladekarl, Morten (author)
-
- Welin, Staffan (author)
- Uppsala universitet,Onkologisk endokrinologi
-
Weber Vestermark, Lene (author)
-
Arola, Johanna (author)
-
Osterlund, Pia (author)
-
Knigge, Ulrich (author)
-
Sørbye, Halfdan (author)
-
- Micke, Patrick (author)
- Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke
-
- Grimelius, Lars (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Grönberg, Malin, 1980- (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Tiensuu Janson, Eva (author)
- Uppsala universitet,Onkologisk endokrinologi
-
show less...
-
(creator_code:org_t)
- 2020-12-14
- 2020
- English.
-
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 15:12
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://journals.plo...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
PLOS ONE
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Ali, Abir Salwa, ...
-
Langer, Seppo W.
-
Federspiel, Birg ...
-
Hjortland, Geir ...
-
Grønbæk, Henning
-
Ladekarl, Morten
-
show more...
-
Welin, Staffan
-
Weber Vestermark ...
-
Arola, Johanna
-
Osterlund, Pia
-
Knigge, Ulrich
-
Sørbye, Halfdan
-
Micke, Patrick
-
Grimelius, Lars
-
Grönberg, Malin, ...
-
Tiensuu Janson, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
PLOS ONE
- By the university
-
Uppsala University